Lincoln Pharmaceuticals Ltd.

₹582.05

-3.6 (-0.6%)

LINCOLN Share Price

Pharmaceuticals & Biotechnology

As on October 1, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 1,166.03 Cr

P/E Ratio13.26

Dividend Yield0.03 %

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	584.97	Bearish
10-DMA	592.38	Bearish
20-DMA	606.44	Bearish
50-DMA	603.83	Bearish
100-DMA	620.26	Bearish
200-DMA	587.59	Bearish

Historical Performance

1 Year

9.4%

3 Years

11.5%

5 Years

48%

10 Years

158.5%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Net Sales	6,710	6,232	5,805	5,103	4,721
Total Expenditure	5,733	5,217	4,806	4,211	3,766
Other Income	335	225	344	225	100
Operating Profit	1,311	1,240	1,343	1,117	1,055
Interest	10	19	15	20	15
Depreciation	145	129	106	92	81
Profit Before Tax	1,156	1,092	1,222	1,005	959
Consolidated Net Profit	879	823	933	729	694
Adjusted EPS	44	41	47	36	35

Compounded Sales Growth

10 Years:10.9

5 Years:9.6

3 Years:5.6

TTM:1.5

Compounded Profit Growth

10 Years:30

5 Years:7.1

3 Years:3.8

TTM:1.3

Stock Price CAGR

10 Years:9.5

5 Years:8.2

3 Years:3.6

TTM:9.3

Return on Equity

10 Years:14.1

5 Years:34.6

3 Years:46.6

last year:43.9

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Share Capital	200	200	200	200	200
Total Reserves	7,376	6,516	5,728	4,824	4,128
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	217	191	152	380	110
Other Current Liabilities	140	148	152	145	98
Short Term Borrowings	44	---	11	20	20
Total Liabilities	9,161	8,219	7,254	6,365	5,546
Capital Work in Progress	52	45	35	67	161
Long Term Loans & Advances	1,110	1,106	797	882	318
Currents Investments	2,085	1,737	1,389	913	968
Short Term Loans and Advances	1,242	809	695	570	676
Total Current Assets	6,088	5,248	4,629	3,911	3,731
Total Assets	9,161	8,219	7,254	6,365	5,546
Adjusted Book Value	378	335	296	251	216

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a moderate PE of 13.26, suggesting fair valuation relative to earnings.
Over the last three years, the stock delivered a weak 3-year price CAGR of 3.6%, indicating poor shareholder returns.
The stock carries a low beta of 0.7, suggesting lower volatility than the broader market.
In the last financial year, the company reported an EBITDA of ₹1311 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹6710 million, suggesting a mid-sized operation.

Investment Calculator

Investment Amount:₹

Investment Amount: ₹ 1000000

Current Value: ₹ 1092949

No. of Shares: 1878 (Approx)

Performance:9.3%

92949

NIFTY Performance: -9.9%

1 day Top Gainers